Last reviewed · How we verify
Nepafenac 0.3% Oph Susp
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin production and inflammation in the eye.
Nepafenac is a nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX) enzymes to reduce prostaglandin production and inflammation in the eye. Used for Reduction of ocular inflammation and associated pain following cataract surgery, Reduction of ocular pain associated with corneal refractive surgery.
At a glance
| Generic name | Nepafenac 0.3% Oph Susp |
|---|---|
| Also known as | Nepafenac 0.3%, NEVANAC EY.DRO.SUS 3MG/ML |
| Sponsor | Actavis Inc. |
| Drug class | Nonsteroidal anti-inflammatory drug (NSAID) |
| Target | COX-1, COX-2 |
| Modality | Small molecule |
| Therapeutic area | Ophthalmology |
| Phase | Phase 3 |
Mechanism of action
Nepafenac is a prodrug that is converted to amfenac in ocular tissues, where it inhibits COX-1 and COX-2 enzymes. This reduces the synthesis of prostaglandins, which are key mediators of inflammation and pain. The ophthalmic suspension formulation delivers the drug directly to the anterior segment of the eye to suppress ocular inflammation.
Approved indications
- Reduction of ocular inflammation and associated pain following cataract surgery
- Reduction of ocular pain associated with corneal refractive surgery
Common side effects
- Ocular irritation or stinging
- Conjunctival hyperemia
- Photophobia
- Corneal erosion or ulceration
Key clinical trials
- Comparing Efficacy of Bromfenac 0.09%, Nepafenac 0.3% and Diclofenac 0.1% in Patients After Cataract Surgery (NA)
- Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension (PHASE3)
- PGE2 Levels in Patient Treated With NSAIDs (PHASE3)
- Comparison of the Efficacy of Nepafenac 0.1% and Nepafenac 0.3 % on Pain Associated With Intravitreal Injections (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Nepafenac 0.3% Oph Susp CI brief — competitive landscape report
- Nepafenac 0.3% Oph Susp updates RSS · CI watch RSS
- Actavis Inc. portfolio CI